Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 495.03M | 385.69M | 270.60M | 50.04M | 0.00 | 0.00 |
Gross Profit | 452.85M | 352.39M | 244.53M | 44.84M | -1.16M | -77.72K |
EBITDA | -224.80M | -272.60M | -224.99M | -174.23M | -123.55M | -99.06M |
Net Income | -246.90M | -287.22M | -239.24M | -197.77M | -134.94M | -105.39M |
Balance Sheet | ||||||
Total Assets | 639.78M | 568.50M | 588.24M | 331.48M | -338.36M | 186.13M |
Cash, Cash Equivalents and Short-Term Investments | 303.02M | 315.35M | 386.19M | 200.84M | 86.47M | 183.88M |
Total Debt | 215.29M | 192.96M | 186.37M | 94.68M | 49.71M | 50.12M |
Total Liabilities | 566.71M | 511.48M | 397.26M | 221.92M | 70.84M | 72.34M |
Stockholders Equity | 73.08M | 57.02M | 190.98M | 109.56M | -409.20M | -278.80M |
Cash Flow | ||||||
Free Cash Flow | -120.51M | -128.68M | -145.66M | -117.21M | -108.53M | -78.50M |
Operating Cash Flow | -120.63M | -128.41M | -145.08M | -116.51M | -108.23M | -78.46M |
Investing Cash Flow | -471.00K | -270.00K | -582.00K | -53.70M | -307.55K | -45.89K |
Financing Cash Flow | 108.46M | 57.84M | 331.01M | 284.58M | 11.13M | 42.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $5.91B | ― | -280.68% | ― | 69.83% | 22.16% | |
55 Neutral | $6.12B | ― | 435.49% | ― | 2635.74% | 4.66% | |
55 Neutral | $6.39B | ― | -1334.54% | ― | 53.55% | 30.87% | |
51 Neutral | $7.93B | -0.35 | -43.30% | 2.25% | 22.54% | -2.22% | |
50 Neutral | $5.76B | ― | -37.76% | ― | 1.23% | -20.45% | |
47 Neutral | $6.11B | ― | -29.70% | ― | 75.01% | -13.20% | |
43 Neutral | $5.80B | ― | -43.55% | ― | ― | -76.16% |
On August 19, 2025, Axsome Therapeutics received a Paragraph IV Certification Notice from Apotex, indicating that Apotex has filed an ANDA with the FDA to produce a generic version of Axsome’s Symbravo®. Axsome plans to respond to this notice, which could impact its market position and stakeholder interests.
On August 4, 2025, Axsome Therapeutics reported a significant financial performance for the second quarter of 2025, with a 72% year-over-year increase in net product revenue, reaching $150 million. The company highlighted the successful launch of SYMBRAVO for migraines and the strong sales growth of AUVELITY and SUNOSI. Axsome is progressing with regulatory submissions for AXS-05 and AXS-12, aiming to expand its product pipeline addressing serious psychiatric and neurological conditions. The company also reported a reduced net loss compared to the previous year, indicating improved financial health.
On June 10, 2025, Axsome Therapeutics announced the commercial availability of SYMBRAVO®, a novel treatment for acute migraine with or without aura in adults. SYMBRAVO offers a multi-mechanistic approach, providing rapid and sustained pain relief, and is supported by comprehensive patient services. This launch addresses a significant unmet need in migraine treatment, potentially benefiting millions of individuals dissatisfied with existing options.